KMT2A and acute myeloid leukemia: Previous reports had highlighted that treatment with the MI SNDX-50469 repressed MLL1 or MLL-FP targets as well as induced in vitro differentiation and loss of viability of AML cells with MLL1-r or mtNPM1 [16, 18].